American Heart Journal
Volume 147, Issue 2 , Pages 239-245 , February 2004

High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study

  • Lidia Arcavi, MD

      Affiliations

    • Clinical Pharmacology Unit, Kaplan Medical Center, Rehovot, affiliated with Hadassah and the Hebrew University School of Medicine, Jerusalem, Israel
    • Corresponding Author InformationReprint requests: Lidia Arcavi, MD, Clinical Pharmacology Unit, Kaplan Medical Center, 76100 Rehovot, Israel.
    • ,
  • Solomon Behar, MD

      Affiliations

    • BIP Study Group, Coordinating Center, Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • Avraham Caspi, MD

      Affiliations

    • Institute of Cardiology, Kaplan Medical Center, Rehovot, Israel
    • ,
  • Naama Reshef, MSc

      Affiliations

    • Metabolic Unit, Kaplan Medical Center, Rehovot, Israel
    • ,
  • Valentina Boyko, MSc

      Affiliations

    • BIP Study Group, Coordinating Center, Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • ,
  • Hilla Knobler, MD

      Affiliations

    • Metabolic Unit, Kaplan Medical Center, Rehovot, Israel

Received 13 November 2002 ,Accepted 5 September 2003.

References 

  1. McCane DR, Hanson RL, Charles MA, et al.  Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308:1323–1328
  2. Engelgau MM, Thompson TJ, Herman WH, et al.  Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes (diagnostic criteria and performance revisited). Diabetes Care. 1997;20:785–791
  3. American Diabetes Association . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  4. Balkau B, Shipley M, Jarrett RJ, et al.  High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care. 1998;21:360–367
  5. Haffner SM, Stern M, Hazuda HP, et al.  Cardiovascular risk factors in the confirmed prediabetic individuals (does the clock for coronary heart disease start ticking before the onset of clinical diabetes?). JAMA. 1990;263:2893–2898
  6. Haffner SM, Mykkanen L, Festa A, et al.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects (implications for preventing coronary heart disease during the prediabetic state). Circulation. 2000;101:975–980
  7. The Bezafibrate Infarction Prevention (BIP) Study Group . Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102:21–27
  8. Goldbourt U, Behar S, Reicher-Reiss H, et al.  Rationale and design of secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease. Am J Cardiol. 1993;71:909–915
  9. Freedman DS, Gruchow HW, Bamrah VS, et al.  Diabetes mellitus and arteriographically documented coronary artery disease. J Clin Epidemiol. 1988;41:659–668
  10. Barzilay JI, Kornmal RA, Bittner V, et al.  Coronary artery disease in diabetic and nondiabetic patients with lower extremity arterial disease (a report from the Coronary Artery Surgery Study Registry). Am Heart J. 1998;135:1055–1062
  11. Farrer M, Fulcher G, Albers CJ, et al.  Patients undergoing coronary artery bypass graft surgery are at increased risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism. 1995;44:1016–1027
  12. Fujiwara R, Kutsumi Y, Hayashi T, et al.  Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol. 1995;75:122–126
  13. Kowalska I, Prokop J, Bachorzewska-Gajewska H, et al.  Disturbances of glucose metabolism in men referred for coronary arteriography. Diabetes Care. 2001;24:897–901
  14. Coutinho M, Gerstein HC, Wang Y, et al.  The relationship between glucose and incident cardiovascular events (a meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years). Diabetes Care. 1999;22:233–240
  15. Barzilay JI, Spiekerman CF, Wahl PW, et al.  cardiovascular disease in older adults with glucose disorders (comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria). Lancet. 1999;354:622–625
  16. The DECODE study group . Glucose tolerance and mortality (comparison of WHO and American Diabetes Association diagnostic criteria). Lancet. 1999;354:617–621
  17. Tominaga M, Eguchi H, Manaka H, et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose (the Funagata Diabetes Study). Diabetes Care. 1999;22:920–924
  18. Fishman EZ, Motro M, Tenenbaum A, et al.  Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease (a marker for a worse prognosis). Am Heart J. 2001;141:485–490
  19. Forrest KY, Becker DJ, Kuller LH, et al.  Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis. 2000;148:159–161
  20. Turner RC, Millns H, Neil HA, et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (United Kingdom Prospective Diabetes Study (UKPDS:23)). BMJ. 1998;316:823–828
  21. UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–853
  22. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 1998;317:703–713
  23. Koskinen P, Manttari M, Manninen V, et al.  Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820–825
  24. Rubins HB, Robins SJ, Collins D, et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. N Eng J Med. 1999;341:410–418
  25. Diabetes Atherosclerosis Intervention Study Investigators . Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes (the Diabetes Atherosclerosis Intervention Study, a randomised study). Lancet. 2001;357:905–910
  26. Pyorala K, Pedersen TR, Kjekshus J, et al.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease (a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)). Diabetes Care. 1997;20:614–620
  27. Goldberg RB, Mellies MJ, Sacks FM, et al.  Cardiovascular events and their reduction with pravastatin in diabetic infarction survivors with average cholesterol levels (subgroup analysis in the cholesterol and recurrent events (CARE) trial. The CARE investigators). Circulation. 1998;98:2513–2519
  28. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med. 1998;339:1349–1357
  29. Haffner SM, Alexander CM, Cook TJ, et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels (subgroup analysis in the Scandinavian Simvastatin Survival Study). Arch Intern Med. 1999;159:2661–2667
  30. American Diabetes Association . Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003;26:S83–86

PII: S0002-8703(03)00654-9

doi: 10.1016/j.ahj.2003.09.013

American Heart Journal
Volume 147, Issue 2 , Pages 239-245 , February 2004

Article Tools

* Image Usage & Resolution